The Asian cancer biotech firm will use ACT's genomic tools to research why some patients responded unusually well to its pan-HER inhibitor.
By Turna Ray
The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.
A small study finds differences between three genomic prostate cancer tests, Medscape reports.
A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.
In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.